---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-039474"
form_type: "8-K"
ticker: "SCNX"
cik: "0001382574"
company_name: "Scienture Holdings, Inc."
filed_at: "2026-08-20T20:05:32+00:00"
generated_at: "2026-08-20T20:07:27.651386+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SCNX Q2 2026: Revenue up ~510% sequentially; net loss narrows 58% YoY

## Summary
- Revenue $343,639 in Q2 2026, up ~510% from $56,325 in Q1 2026; H1 revenue $399,964 vs $10,258 in H1 2025.
- Net loss narrowed ~58% YoY to ~$2.8M; EPS improved to -$0.07 from -$0.48; operating loss ~$2.7M, down ~48%.
- Cash, equivalents and restricted cash ~$11.2M at June 30, 2026, vs ~$6.7M at Dec 31, 2025; gross margin ~97.7%.
- Commenced commercial launch of REZENOPY (naloxone nasal spray); second patent granted through 2041.
- Arbli expanded payer coverage adding ~12.5M covered lives; third patent granted; targeting profitability in 2027.

## SEC filing metadata
- accession: 0001493152-26-039474
- form_type: 8-K
- ticker: SCNX
- cik: 0001382574
- company_name: Scienture Holdings, Inc.
- filed_at: 2026-08-20T20:05:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382574/000149315226039474/0001493152-26-039474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382574/000149315226039474/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-039474
- JSON: https://secwatch.observer/filing/0001493152-26-039474.json
- Plain text: https://secwatch.observer/filing/0001493152-26-039474.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.